Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026104 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT00026104: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00026104 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 154 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026104, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally advanced pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy and radiation therapy with tipifarnib may be an effective treatment for pancreatic cancer.
Interventions
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG gemcitabine hydrochloride
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2001-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026104
The ClinicalTrials.gov registry entry for NCT00026104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which paclitaxel is the first listed.
NCT00026104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026104 about?
NCT00026104 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer". Randomized phase II trial to compare the effectiveness of gemcitabine, paclitaxel, and radiation therapy with or without tipifarnib in treating patients who have locally advanced pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing o...
What is the current status of trial NCT00026104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2001-11.
What interventions are being tested in trial NCT00026104?
The interventions under investigation include: paclitaxel (DRUG), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00026104?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.